NGM Bio Secures $122 Million in Series A to Launch Primary Sclerosing Cholangitis Trial and Support Phase 2 Hyperemesis Gravidarum Study.

Immutep Gets Approval for Phase I Trial of Novel LAG-3 Agonist Antibody Targeting Autoimmune Disorders.

Biotheryx Initiates Phase 1 Trial, Administers Initial Dose of BTX-9341, a Novel Dual Action CDK4/6 Degrader, Alone and with Other Treatments.

Atara Biotherapeutics announced that the FDA has granted priority review for its Tab-cel® application to treat EBV+ PTLD.

4DMT reports encouraging Phase 2 PRISM interim outcomes for Intravitreal 4D-150 in diverse wet AMD patients, confirming positive safety and strong clinical efficacy.

Bayer reveals promising primary results for NUBEQA® (darolutamide) from a Phase III study in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Genentech Reports Promising Phase I Outcomes for Oral GLP-1 Receptor Agonist CT-996 in Obesity Treatment.

NexThera Co., Ltd. announced the submission of a Phase 1/2a Investigational New Drug application to the U.S. Food and Drug Administration for NT-101.

Celldex Therapeutics launches worldwide Phase 3 trial of Barzolvolimab for chronic spontaneous urticaria patients.

Novo Holdings spearheads $100 million Series C investment in Asceneuron to propel innovative Alzheimer’s treatment forward.

Biosyngen's BRG01 moves to Phase II trial, pioneering autologous EBV-specific CAR-T for recurrent/metastatic nasopharyngeal carcinoma solid tumors.

Evommune, Inc. reported positive findings from its initial proof-of-concept study in humans with EVO756.